Sunnyside Unified trust board reviews year‑end health plan finances; early 2024–25 shows two‑month loss

The Sunnyside Unified District trust board reviewed its employee health plan finances Sept. 19, hearing that the 2023–24 plan year finished with roughly $9.9 million in revenue and about $1.5 million in net income, but that the early 2024–25 results show a near‑term gap driven by medical and prescription claims.

Stephanie, the plan presenter, told the board the plan recorded contributions of about $8,000,000 for the July 2023–June 2024 year and total revenues near $9.9 million, an increase of roughly $480,000 from the prior year. Total expenses for the year were about $8.42 million — roughly $370,000 higher than the prior year — leaving net income of about $1.5 million after accounting for stop‑loss recoveries and incurred‑but‑not‑reported adjustments. Stephanie also reported the trust’s year‑end assets and liabilities were about $9.8 million on the balance sheet.

Nut graf: The figures matter because they determine whether current contribution and funding rates are adequate for the coming year. Board materials and staff presentations showed mixed signals — a positive full‑year result for 2023–24 but a material early‑year deficit for 2024–25 — prompting staff to recommend monitoring but not immediate rate changes.

Board members were shown month‑by‑month activity and told prescription claims and a handful of large claimants were notable cost drivers. Chris, the plan analyst, reported total paid claims for the 2023–24 year of about $5.1 million and total paid claims plus other costs of about $6.3 million, producing an overall loss ratio near 77 percent. He said 13 large claimants accounted for roughly 27–28 percent of total paid claims, and that some prescription costs rose after certain drugs (including Humira) returned to payer formularies; those changes also increased rebate activity.

For the first two months of the 2024–25 plan year (July–August), Stephanie said revenue was about $955,000 versus expenses near $1.9 million, producing a net loss of about $959,000. She noted some stop‑loss reimbursements posted early in the plan year likely related to prior policy years and recommended staff follow up to clarify timing and attribution.

On premium adequacy, Chris reviewed the funding rates used for 2024–25 and said the modeled change versus implemented funding was –7.9 percent and versus current was –2 percent; based on that analysis, he did not recommend immediate rate changes but advised continued monitoring of enrollment shifts and drug‑rebate developments.

Board discussion included questions about whether higher enrollment or staffing changes had driven cost shifts; a board member, Linda, suggested the recent enrollment increase reflected employees regaining eligibility and access to coverage. Chris and Stephanie answered technical questions about enrollment mix (noting the majority of members are in a high‑deductible plan) and headcount detail for PPO participants.

The board also heard two brief district updates: the chair said both district wellness positions were filled in July and praised a bilingual wellness specialist’s outreach; he announced the launch of a “healthiest u” app and noted utilization reports are expected by the next meeting.

Procedural items: the board approved the meeting agenda and the minutes from the prior May meeting by voice vote and later moved to adjourn. No substantive policy actions, rate changes or formal authorizations were taken at the meeting; staff were directed to continue monitoring claims experience and to report back as needed.

What’s next: Staff will follow up on the timing of stop‑loss reimbursements, monitor prescription rebates and enrollment trends, and the board is expected to receive a first‑quarter report at the next meeting.